Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huashi Baidu Granule
- Development stage
- Unknown
- Lead developer
- Guangdong Yifang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Huashi Baidu Granule is a traditional Chinese medicine (TCM) formula composed of multiple herbal ingredients. It was developed and clinically approved in China for the treatment of COVID-19. The granule has demonstrated antiviral and anti-inflammatory effects in both preclinical and clinical studies. Its mechanism includes inhibition of viral replication (notably SARS-CoV-2), suppression of inflammatory cytokines (such as IL-1β, IL-6, IL-8, TNF-α), and modulation of pathways involved in lung fluid clearance by upregulating AQP1, AQP5, α-ENaC, and Na-K-ATPase expression. Key bioactive compounds identified include magnolol, glycyrrhisoflavone, licoisoflavone A, emodin, echinatin, quercetin (antiviral activity), licochalcone B (anti-inflammatory activity), among others. Clinical trials have shown that early treatment with this granule reduces symptom worsening in mild COVID-19 cases and is comparable to Paxlovid for severe cases[1][2][3][6].
- Brand names
- Huashi Baidu GranuleHuashibaidu granuleHuashi Baidu decoctionQ-14Q14Q 14
- Other names
- HSBDGHSBDHSBDF
02
Targets
AQP1 (Aquaporin-1)AQP5 (Aquaporin-5)CASP1 (Caspase-1)SCNN1A (ENaC alpha subunit)GSDMD-NT (Gasdermin D N-terminal fragment)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)RdRp (Coronavirus RNA-dependent RNA polymerase)PDE4D (Phosphodiesterase 4D)Mpro (3C-like proteinase of SARS-CoV-2)ATP1A (Sodium/potassium-transporting ATPase)PDE4 (Phosphodiesterase 4A1)
Beyond the preview
Go deeper on Huashi Baidu Granule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Huashi Baidu Granule.